Drug Profile
OMTX 703
Alternative Names: MTX3-CYT; OMTX-703Latest Information Update: 09 Sep 2020
Price :
$50
*
At a glance
- Originator Oncomatryx
- Class Antineoplastics; Immunoconjugates; Immunotoxins
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Ewing's sarcoma; Soft tissue sarcoma; Uveal melanoma
- No development reported Pancreatic cancer
Most Recent Events
- 09 Sep 2020 Preclinical development for Ewing's sarcoma is ongoing in Spain (Oncomatryx pipeline, September 2020)
- 09 Sep 2020 Preclinical trials in Ewing's Sarcoma in Spain (unspecified route)
- 09 Sep 2020 Preclinical trials in Sarcoma in Spain (unspecified route)